Versant Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Versant Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-62	Closed	-$545	–	1962
2023 Q4	$545	Buy	+62	New	+$508	﹤0.01%	1656
2023 Q3	–	Sell	-14	Closed	-$354	–	2082
2023 Q2	$354	Buy	+14	New	+$436	﹤0.01%	1897
2021 Q4	–	Sell	-12	Closed	–	–	1621
2021 Q3	$0	Hold	12	–	–	﹤0.01%	1636
2021 Q2	$0	Hold	12	–	–	﹤0.01%	1628
2021 Q1	$0	Hold	12	–	–	﹤0.01%	1627
2020 Q4	$0	Hold	12	–	–	﹤0.01%	1571
2020 Q3	$0	Hold	12	–	–	﹤0.01%	1548
2020 Q2	$0	Hold	12	–	–	﹤0.01%	1603
2020 Q1	$0	Buy	+12	New	+$248	﹤0.01%	1748

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versant Capital Management's RVNC Position: Q1 2024 in Review

Versant Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 62 shares — an estimated $545 sold.

Versant Capital Management first reported a position in RVNC in Q1 2020 and held it in 9 quarters. The position peaked at $545 in Q4 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

Versant Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Versant Capital Management sold 62 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $545.
Versant Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 9 quarters.
Versant Capital Management's Revance Therapeutics, Inc. position peaked at $545 in Q4 2023.
188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Versant Capital Management's 13F filing for Q1 2024, filed 3 Apr 2024.